Compare VSME & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VSME | CLGN |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 5.2M |
| IPO Year | 2022 | 2015 |
| Metric | VSME | CLGN |
|---|---|---|
| Price | $1.05 | $4.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 100.3K | 46.6K |
| Earning Date | 04-30-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $0.26 |
| 52 Week High | $5.38 | $4.78 |
| Indicator | VSME | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 60.67 | 58.29 |
| Support Level | $1.05 | $0.34 |
| Resistance Level | $1.16 | $4.62 |
| Average True Range (ATR) | 0.10 | 0.34 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 97.86 | 53.49 |
VS Media Holdings Ltd manages a network of digital Creators who create and publish content to social media platforms such as YouTube, Facebook, Instagram, and TikTok. Its Creators include influencers, KOLs-Key Opinion Leaders, bloggers, and other content creators who cultivate fan bases on social media platforms. The company's business provides value to two business stakeholders: marketing services and social commerce. The firm generates almost all of its revenue from marketing services, which reflects the company's business of marketing services to clients and social media platforms. The social commerce segment reflects the company's business of social commerce with customers. Geographically, the firm generates revenue from the HK SAR and Taiwan.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.